GLP1R and inflammatory bowel disease: Pham et al. compared the use of anti-obesity medications (AOMs), a subset of which were GLP-1 receptor agonists, in 36 IBD patients compared to 36 non-IBD controls and found no significant impact on the frequency of IBD exacerbations (which occurred in 7 patients, 19.4%), defined as the need for steroid use, a change in IBD therapy, hospitalization, and surgery compared to pre-treatment status [37].